Needham Raises Price Target on Pulse Biosciences to $64
Needham & Co. increased its price target for Pulse Biosciences, Inc. from $58 to $64 while maintaining a Buy rating.
Stocks · News reference
Pulse Biosciences Presents Six-Month Interim Results from PRECISE-BTN Study
Pulse Biosciences announced positive six-month interim results from its PRECISE-BTN multicenter study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — PULSE BIOSCIENCES, INC. (PLSE)
Filed: 2026-11-06 AccNo: 0001437749-26-035410 Size: 183 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results
Pulse Biosciences announced its financial results for the third quarter ended September 30, 2026, and highlighted the completion of enrollment in its U.S. pivotal IDE study.
Pulse Biosciences to Present at Stifel 2026 Healthcare Conference
Pulse Biosciences, Inc. announced its scheduled participation and management presentation at the upcoming Stifel 2026 Healthcare Conference.
Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call
Pulse Biosciences has scheduled its third quarter 2026 financial results conference call for November 5, 2026.
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its